Beijing New Oriental Star Petrochemical Engineering Co Ltd - Asset Resilience Ratio
Beijing New Oriental Star Petrochemical Engineering Co Ltd (002755) has an Asset Resilience Ratio of 24.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Beijing New Oriental Star Petrochemical Engineering Co Ltd's Asset Resilience Ratio has changed over time. Check Beijing New Oriental Star Petrochemical strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Beijing New Oriental Star Petrochemical Engineering Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002755 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.09 Billion | 24.59% |
| Total Liquid Assets | CN¥1.09 Billion | 24.59% |
Asset Resilience Insights
- Good Liquidity Position: Beijing New Oriental Star Petrochemical Engineering Co Ltd maintains a healthy 24.59% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Beijing New Oriental Star Petrochemical Engineering Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing New Oriental Star Petrochemical Engineering Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621 |
Drug Manufacturers - Specialty & Generic | 2.04% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
|
Jw Pharmac
KO:001060 |
Drug Manufacturers - Specialty & Generic | 3.65% |
|
Kamada
TA:KMDA |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Samjin Pharm
KO:005500 |
Drug Manufacturers - Specialty & Generic | 0.25% |
Annual Asset Resilience Ratio for Beijing New Oriental Star Petrochemical Engineering Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Beijing New Oriental Star Petrochemical Engineering Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 16.88% | CN¥683.28 Million ≈ $99.99 Million |
CN¥4.05 Billion ≈ $592.30 Million |
-3.38pp |
| 2023-12-31 | 20.26% | CN¥713.83 Million ≈ $104.46 Million |
CN¥3.52 Billion ≈ $515.65 Million |
-4.32pp |
| 2022-12-31 | 24.57% | CN¥839.08 Million ≈ $122.78 Million |
CN¥3.41 Billion ≈ $499.63 Million |
+10.55pp |
| 2021-12-31 | 14.02% | CN¥522.39 Million ≈ $76.44 Million |
CN¥3.72 Billion ≈ $545.05 Million |
+11.40pp |
| 2020-12-31 | 2.63% | CN¥100.00 Million ≈ $14.63 Million |
CN¥3.81 Billion ≈ $557.24 Million |
-0.08pp |
| 2019-12-31 | 2.71% | CN¥100.00 Million ≈ $14.63 Million |
CN¥3.69 Billion ≈ $540.27 Million |
+1.69pp |
| 2018-12-31 | 1.01% | CN¥30.00 Million ≈ $4.39 Million |
CN¥2.96 Billion ≈ $432.89 Million |
-79.94pp |
| 2015-12-31 | 80.96% | CN¥580.00 Million ≈ $84.87 Million |
CN¥716.42 Million ≈ $104.84 Million |
-- |
About Beijing New Oriental Star Petrochemical Engineering Co Ltd
Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in oncology, antibiotic, and other areas. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 2003 and is bas… Read more